Compares treatment plans for HIV that stops working in Africa
Tests ways to manage HIV treatment failure in people taking TLD in Africa.
Plain-language title generated from the registry record
Registry title: A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa
Key facts
- Where
- Mbarara, UgandaSee the 2 sites
Where in Uganda
- Mbarara City ClinicMbarara, UgandaTaking people
- Mbarara Regional Referral Hospital Immune Suppression Syndrome ClinicMbarara, UgandaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Massachusetts General Hospital
- Trial code
- NCT05373758
- Record updated
- 19 March 2026
- Original description
The RESOLVE trial is an open, parallel arm, randomized clinical trial which aims to determine the optimal strategy for management of virologic failure on antiretroviral therapy (ART) with tenofovir, lamivudine, and dolutegravir (TLD) in sub-Saharan Africa. The primary outcome of interest will be viral suppression to <50 copies/mL at 48 weeks using the FDA snapshot definition. The study will be conducted in Uganda and South Africa.Read full original descriptionShow less
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure for Individuals on Tenofovir, Lamivudine, and Dolutegravir (TLD) in Sub-Saharan Africa
The RESOLVE trial is an open, parallel arm, randomized clinical trial which aims to determine the optimal strategy for management of virologic failure on antiretroviral therapy (ART) with tenofovir, lamivudine, and dolutegravir (TLD) in sub-Saharan Africa. The primary outcome of interest will be viral suppression to <50 copies/mL at 48 weeks using the FDA snapshot definition. The study will be conducted in Uganda and South Africa.
Inclusion: Age 15 years and above; Enrolled in HIV care at one of the study clinics; History of two HIV-1 RNA viral load measurements >1,000 copies/mL while on TLD; On TLD for at least 12 months; Lives within 100 kilometers of study clinic; Pregnant women are eligible for enrollment.
Exclusion: As determined by chart review, we will exclude those with known virologic failure on protease inhibitors or exposure to integrase strand transfer inhibitors other than dolutegravir; Plans to transfer out of the clinic within the next 48 weeks; Plans to move out of the study catchment area within the next 48 weeks.